ミシガン州における肺がんの臨床試験
ミシガン州内の拠点で、肺がんに関する44件の研究が参加者を募集しています。
ミシガン州内の都市
- Ann Arbor23件の研究
- Detroit20件の研究
- Grand Rapids14件の研究
- Lansing11件の研究
- Livonia10件の研究
- Flint10件の研究
- Canton9件の研究
- Waterford9件の研究
- Farmington Hills8件の研究
- Saginaw6件の研究
- Troy6件の研究
- Warren6件の研究
- Kalamazoo6件の研究
- Dearborn6件の研究
- Clinton Township6件の研究
- Wyoming5件の研究
- Jackson3件の研究
公式研究テキスト（英語）
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
- Trinity Health Saint Joseph Mercy Hospital Ann Arbor, Ann Arbor
- Bronson Battle Creek, Battle Creek
- Trinity Health IHA Medical Group Hematology Oncology - Brighton, Brighton
- 他50件
被験者募集中第3相
18歳以上 · 全性別 · 2026/10/02更新 · NCT04267848Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
- MyMichigan Medical Center Gratiot, Alma
- MyMichigan Medical Center Alpena, Alpena
- Trinity Health Saint Joseph Mercy Hospital Ann Arbor, Ann Arbor
- 他68件
被験者募集中観察研究健康なボランティア歓迎
40歳〜75歳 · 全性別 · 2026/10/02更新 · NCT05334069Chemotherapy Combined With Immunotherapy Versus Immunotherapy Alone for Older Adults With Stage IIIB-IV Lung Cancer, The ACHIEVE Trial
- Bronson Battle Creek, Battle Creek
- Trinity Health IHA Medical Group Hematology Oncology - Brighton, Brighton
- Trinity Health IHA Medical Group Hematology Oncology - Canton, Canton
- 他20件
被験者募集中第3相
70歳以上 · 全性別 · 2026/10/01更新 · NCT06096844Osimertinib With or Without Bevacizumab as Initial Treatment for Patients With EGFR-Mutant Lung Cancer
- Trinity Health Saint Joseph Mercy Hospital Ann Arbor, Ann Arbor
- Trinity Health IHA Medical Group Hematology Oncology - Brighton, Brighton
- Trinity Health Medical Center - Brighton, Brighton
- 他27件
被験者募集中第3相
18歳以上 · 全性別 · 2026/10/01更新 · NCT04181060Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial
- University of Michigan Rogel Cancer Center, Ann Arbor
- Bronson Battle Creek, Battle Creek
- Trinity Health IHA Medical Group Hematology Oncology - Brighton, Brighton
- 他38件
被験者募集中第3相
18歳以上 · 全性別 · 2026/10/01更新 · NCT06498635Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)
- Trinity Health Ann Arbor Hospital, Ann Arbor
- Karmanos Cancer Institute, Detroit
- Henry Ford Health, Detroit
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/29更新 · NCT06881784This is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in People With Non-small Cell Lung Cancer With High Levels of PD-L1.
- Corewell Health - Butterworth Hospital, Grand Rapids
- Corewell Health - Lemmen Holton Cancer Pavilion, Grand Rapids
- Corewell Health - Research Specimen Processing Area, Grand Rapids
- 他2件
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/25更新 · NCT06758401A Registry for People With Lung Cancer
- University of Michigan (Data Collection Only), Ann Arbor
被験者募集中観察研究
18歳以上 · 全性別 · 2026/09/24更新 · NCT06424327A Study to Compare the Combination of Navlimetostat (BMS-986504) With Pembrolizumab and Chemotherapy Versus Placebo Plus Pembrolizumab and Chemotherapy in First-line Metastatic Non-small Cell Lung Cancer Participants With Homozygous MTAP Deletion
- Local Institution - 0418, Ann Arbor
- Local Institution - 0405, Detroit
- Local Institution - 0420, Traverse City
被験者募集中第2/3相
18歳以上 · 全性別 · 2026/09/23更新 · NCT07063745Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors
- START Midwest, Grand Rapids
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/09/22更新 · NCT06128551A First-in-Human Trial of BLU-924 (SAR449336) in Advanced Solid Tumors Harboring KRAS Mutations
- University of Michigan Medical School Rogel Cancer Center, Ann Arbor
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/09/21更新 · NCT07629960Study of RMC-5127 in Patients With Advanced KRAS G12V-Mutant Solid Tumors
- START Midwest, Grand Rapids
被験者募集中第1相
18歳以上 · 全性別 · 2026/09/17更新 · NCT07349537Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies
- South Texas Accelerated Research Therapeutics (START) Midwest, Grand Rapids
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/09/16更新 · NCT05786924Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors
- Karmanos Cancer Institiute, Detroit
被験者募集中第1相
18歳以上 · 全性別 · 2026/09/10更新 · NCT06293898A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
- Profound Research, LLC, Farmington Hills
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/08更新 · NCT06793215A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
- University of Michigan, Ann Arbor
- The Cancer & Hematology Centers, Grand Rapids
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/08更新 · NCT06119581A Study of Sofe-M in Participants With Selected Advanced Solid Tumors
- South Texas Accelerated Research Therapeutics (START) Midwest, Grand Rapids
被験者募集中第1相
18歳以上 · 全性別 · 2026/09/04更新 · NCT06400472Open-label Study of BBO-8520 in Adult Subjects With KRASG12C Non-small Cell Lung Cancer
- Henry Ford Cancer - Detroit, Detroit
被験者募集中第1相
18歳以上 · 全性別 · 2026/09/03更新 · NCT06343402The Vanguard Study: Testing a New Way to Screen for Cancer
- Henry Ford Cancer Institute-Downriver, Brownstown
- Henry Ford Health Center - Brownstown, Brownstown
- Henry Ford Health Center - Chesterfield, Chesterfield
- 他13件
被験者募集中健康なボランティア歓迎
45歳〜75歳 · 全性別 · 2026/09/02更新 · NCT06995898Study to Evaluate Efficacy and Safety of Firmonertinib Compared With Investigator's Choice of EGFR Inhibitor as First-Line Treatment in Participants Who Have Locally Advanced or Metastatic NSCLC With EGFR P-Loop and Alpha C-Helix Compressing (PACC) Uncommon Mutations
- Henry Ford Cancer Institute, Detroit
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/01更新 · NCT07185997Evaluation of the Safety and Efficacy of Abenacianine (VGT-309) to Identify Cancer in Subjects Undergoing Surgery for Cancer in the Lung
- University of Michigan, Ann Arbor
被験者募集中第3相
18歳以上 · 全性別 · 2026/08/19更新 · NCT07499674Testing Proton Craniospinal Radiation Therapy Versus the Usual Radiation Therapy for Leptomeningeal Metastasis, RADIATE-LM Trial
- Wayne State University/Karmanos Cancer Institute, Detroit
- Weisberg Cancer Treatment Center, Farmington Hills
- McLaren Cancer Institute-Flint, Flint
- 他1件
被験者募集中第3相
18歳以上 · 全性別 · 2026/08/17更新 · NCT06500481Testing the Addition of High Dose, Targeted Radiation to the Usual Treatment for Locally-Advanced Inoperable Non-Small Cell Lung Cancer
- Trinity Health Saint Joseph Mercy Hospital Ann Arbor, Ann Arbor
- McLaren Cancer Institute-Bay City, Bay City
- Trinity Health IHA Medical Group Hematology Oncology - Brighton, Brighton
- 他41件
被験者募集中第3相
18歳以上 · 全性別 · 2026/08/17更新 · NCT05624996A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors
- Karmanos Cancer Institute, Detroit
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/08/11更新 · NCT05592626Study Evaluating the Safety and Efficacy of HWK-007, a PTK7-directed Antibody Drug Conjugate in Participants With Advanced Solid Tumors
- START - Midwest, Grand Rapids
被験者募集中第1相
18歳以上 · 全性別 · 2026/08/05更新 · NCT07444814Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)
- Henry Ford Cancer Institute, Detroit
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/07/29更新 · NCT04198766Study of Sacituzumab Govitecan With Atezolizumab/Durvalumab as Maintenance Therapy for Extensive-Stage Small Cell Lung Cancer
- Henry Ford Cancer- Detroit, Detroit
被験者募集中第2相
18歳以上 · 全性別 · 2026/07/28更新 · NCT07339059Study of RAS(ON) Inhibitors in Patients With Advanced RAS-mutated NSCLC
- Henry Ford Cancer - Detroit (Brigitte Harris Cancer Pavilion), Detroit
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/06/30更新 · NCT06162221Gilteritinib for the Treatment of ALK NSCLC
- University of Michigan Comprehensive Cancer Center, Ann Arbor
被験者募集中第1相
18歳以上 · 全性別 · 2026/06/26更新 · NCT06225427Prediction Augmented Screening Initiative
- VA Ann Arbor Healthcare System, Ann Arbor, MI, Ann Arbor
被験者募集中
50歳〜80歳 · 全性別 · 2026/06/26更新 · NCT06538636Autologous LN-145 in Patients With Metastatic Non-Small-Cell Lung Cancer
- Karmanos Cancer Institute, Detroit
被験者募集中第2相
18歳〜70歳 · 全性別 · 2026/06/26更新 · NCT04614103Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)
- Trinity Health Saint Joseph Mercy Hospital Ann Arbor, Ann Arbor
- Trinity Health IHA Medical Group Hematology Oncology - Brighton, Brighton
- Trinity Health Medical Center - Brighton, Brighton
- 他19件
被験者募集中第2相
18歳以上 · 全性別 · 2026/06/03更新 · NCT05642572A Study of ZW251 in Participants With Advanced Solid Tumors
- START Midwest, Grand Rapids
被験者募集中第1相
18歳以上 · 全性別 · 2026/05/07更新 · NCT07164313Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial)
- Trinity Health Saint Joseph Mercy Hospital Ann Arbor, Ann Arbor
- Trinity Health IHA Medical Group Hematology Oncology - Brighton, Brighton
- Trinity Health Medical Center - Brighton, Brighton
- 他14件
被験者募集中第2相
18 Minutes · 全性別 · 2026/05/05更新 · NCT06031688Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)
- Trinity Health IHA Medical Group Hematology Oncology - Brighton, Brighton
- Trinity Health IHA Medical Group Hematology Oncology - Canton, Canton
- Trinity Health IHA Medical Group Hematology Oncology - Chelsea Hospital, Chelsea
- 他7件
被験者募集中第2/3相
18歳以上 · 全性別 · 2026/05/05更新 · NCT06616584A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors
- University of Michigan, Ann Arbor
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/04/22更新 · NCT07020221A Study Evaluating FMC-376 in Participants With KRAS G12C Mutated Solid Tumors
- Karmanos Cancer Institute, Detroit
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/03/18更新 · NCT06244771Veterans Affairs Lung Cancer Surgery Or Stereotactic Radiotherapy
- VA Ann Arbor Healthcare System, Ann Arbor, MI, Ann Arbor
被験者募集中
18歳以上 · 全性別 · 2026/02/19更新 · NCT02984761EZH2 Inhibitor, Tulmimetostat, and PD-1 Blockade for Treatment of Advanced Non-small Cell Lung Cancer
- VA Ann Arbor Healthcare System, Ann Arbor, MI, Ann Arbor
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/01/27更新 · NCT05467748A Self-Monitoring Platform for Tracking Medication Safety and Concerns in Cancer Patients
- University of Michigan Comprehensive Cancer Center, Ann Arbor
被験者募集中
18歳以上 · 全性別 · 2026/01/21更新 · NCT07291414ClinicalTrials.govより、2026/10/05時点のデータを取得。各研究には独自の参加資格があり、参加可否は研究チームが決定します。